Remove tag patient-involvement
article thumbnail

STAT+: A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available

STAT

The deals will initially involve manufacturing cell therapies for combating lymphoma and leukemia, which carry price tags in the hundreds of thousands of dollars in wealthy nations. By

130
130
article thumbnail

Skin tag on eyelid: Causes and treatment

The Checkup by Singlecare

Skin tags , also called acrochordons, are harmless growths that can occur anywhere on your body but tend to develop in more friction-heavy areas like the armpit, the neck along the seat belt line where clothes and jewelry touch, under the breasts, in the groin, or on the face—specifically, the eyelid. What causes skin tags on eyelids?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

PharmaShots Weekly Snapshots (April 17 - 21, 2023)

PharmaShots

Oblato Reports the First Patient Enrolment of OKN-007 in the P-I Clinical Trial for Recurrent High-Grade Glioma Date: Apr 21, 2023 | Tags: Oblato, OKN-007, Recurrent High-Grade Glioma, Regulatory, Henry Ford Health System CARsgen's CT041 Receives the US FDA’s IND Clearance for the Postoperative Adjuvant Therapy of Pancreatic Cancer Date: (..)

FDA 40
article thumbnail

FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag

pharmaphorum

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. overall response rate (ORR) in patients with high levels of c-Met expression, and 25% in those with intermediate levels, showing proof of concept for the ADC.

FDA 111
article thumbnail

Cartherics grants licence for CTH-004 to Shunxi

Pharmaceutical Technology

CTH-004 is developed by genetically altering patient T cells for inserting a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes which are involved in T cell function suppression. Topic sponsors are not involved in the creation of editorial content.

52
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. For example, in Sweden, the proposed arrangement for Sanofi / Regeneron’s Dupixent (dupilumab) included a tripartite price negotiation involving Sanofi, the Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket, TLV), and local councils.

FDA 105
article thumbnail

Drug-resistant epilepsy drug Ontozry backed by NICE

pharmaphorum

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. An opinion from the Scottish Medicine Consortium (SMC) on the use of the drug by NHS Scotland is expected to be published early in 2022.